A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

1. Inclusion Criteria:

   1.1 Patients clinically evaluated and radiologically examined (including MRI, particularly T2WI and DWI sequences) who are diagnosed with uterine leiomyoma or considered highly suspected of uterine sarcoma, in combination with preliminary pathological findings.

   1.2 Patients scheduled for surgical treatment or those eligible for long-term standardized follow-up.

   1.3 Patients who are able to understand the study procedures and voluntarily sign the written informed consent form.
2. Exclusion Criteria:

2.1 Patients with severe organic diseases or a previous confirmed diagnosis of other malignant uterine tumors.

2.2 Patients unable to complete baseline examinations, unable to comply with long-term follow-up, or unwilling to provide written informed consent.